Chinese Generic Drug, Device Makers Big Beneficiaries Of Beijing’s Healthcare Reforms
This article was originally published in PharmAsia News
Executive Summary
Analysts observe that competitive pharmaceutical companies, especially big ones, will be the first to enjoy China's RBM 850 billion in funding for healthcare reforms. Domestic players, especially those in the medical device sector, will have an edge due to lower costs. However, overseas drug and device makers are likely to change their previous strategy and make inroads into the third-tier market. TCM will be included in the revised essential drug catalog, bringing it unprecedented opportunities. Chain drugstores do not see much benefit for now and are awaiting more specific rules on reform of hospital income from drug sales. Software service providers, such as IBM, see potential in moving into the rural areas. Private health insurance will see the market shrink due to public insurance expansion, but this is expected to spur private insurance outifts to offer more innovative products. (Click here for more - Chinese Language)
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.